SCHEMBL940958

SCHEMBL940958

O=C(O)c1cc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TYR P14679 4/20 0.61
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
AKR1B1 P15121 1/20 0.55
DPP4 P27487 1/20 0.55
POLB P06746 1/20 0.53
PTPN1 P18031 1/20 0.53
SLC28A3 Q9HAS3 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635640 0.90 NPC1 (0.68) TYRNPC1RAB9AAKR1B1DPP4
SCHEMBL940963 0.87 APP (0.62) TYRNPC1RAB9AAKR1B1DPP4
SCHEMBL943281 0.85 NPC1 (0.57) TYRNPC1RAB9AAKR1B1DPP4
SCHEMBL941369 0.84 NPC1 (0.56) TYRNPC1RAB9AAKR1B1DPP4
SCHEMBL941363 0.83 NPC1 (0.55) TYRNPC1RAB9AAKR1B1DPP4
SCHEMBL28346617 0.82 NPC1 (0.74) TYRNPC1RAB9AAKR1B1DPP4
SCHEMBL940961 0.81 SLC5A2 (0.54) TYRNPC1RAB9APTPN1SLC28A3
SCHEMBL5824275 0.81 TYR (0.66) TYRNPC1RAB9APOLBCA12
SCHEMBL5824276 0.81 TYR (0.66) TYRNPC1RAB9APOLBCA12
SCHEMBL29777490 0.81 TYR (0.66) TYRNPC1RAB9APOLBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136940-A Method for simply and conveniently synthesizing 5-O- (beta-D-glucopyranosyl) gentisic acid 北京化工大学 2025-06-13 CN claimed
CN-120136940-A Method for simply and conveniently synthesizing 5-O- (beta-D-glucopyranosyl) gentisic acid 北京化工大学 2025-06-13 CN disclosed
CN-120136940-A Method for simply and conveniently synthesizing 5-O- (beta-D-glucopyranosyl) gentisic acid 北京化工大学 2025-06-13 CN disclosed
CN-120136940-A Method for simply and conveniently synthesizing 5-O- (beta-D-glucopyranosyl) gentisic acid 北京化工大学 2025-06-13 CN disclosed
CN-119044387-A Identification method of radix codonopsis origin and production place 中国中医科学院中药研究所 2024-11-29 CN disclosed
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20110014141-A1 TOPICAL AGENT FOR DERMATOLOGICAL USE DSM IP ASSETS B.V. (NL) 2011-01-20 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed
EP-1859835-A2 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside PENTAPHARM Ltd. (CH) 2007-11-28 EP disclosed
US-20030198610-A1 Topical agent for dermatological use DSM IP ASSETS B.V. (NL) 2003-10-23 US disclosed
EP-1289489-A2 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM Ltd. (CH) 2003-03-12 EP disclosed
WO-2001091715-A2 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM LTD. (CH) 2001-12-06 WO disclosed
EP-0649648-B1 Skin whitening agents containing glycosides SHISEIDO CO LTD (JP) 2001-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014141-A1 TOPICAL AGENT FOR DERMATOLOGICAL USE GALE, ALPP, UGGT1 TYR 9/4885NPC1 2633/4885RAB9A 4832/4885
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 TYR 149/4885NPC1 4440/4885RAB9A 4230/4885
US-20030198610-A1 Topical agent for dermatological use GALE, UGGT1, UGDH TYR 6/4885NPC1 2969/4885RAB9A 4806/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 TYR 113/4885NPC1 4374/4885RAB9A 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.